Skip to main content

Table 1 Baseline characteristics of the subjects

From: Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial

  SQT (n = 195) PBAT (n = 195) p-value
Gender, n (%)    0.184
 Male 103 (52.8) 117 (60.0)  
 Female 92 (47.2) 78 (40.0)  
Age (mean ± SD), year 53.1 ± 12.6 53.6 ± 13.2 0.697
BMI, kg/m2 23.5 ± 3.1 23.9 ± 3.4 0.328
Smoking, n (%) 38 (19.5) 36 (18.5) 0.897
Alcohol, n (%) 75 (38.5) 72 (36.9) 0.835
Endoscopic finding, n (%)    
 Normal 10 (5.1) 11 (5.6) 1.000
 Atrophic gastritis with or without intestinal metaplasia 43 (22.1) 31 (15.9) 0.155
 Other gastritis 12 (6.2) 16 (8.2) 0.556
 Gastric ulcer 47 (24.1) 43 (22.1) 0.718
 Duodenal ulcer 15 (7.7) 20 (10.3) 0.479
 Gastric ulcer + Duodenal ulcer 4 (2.1) 7 (3.6) 0.541
 EMR, ESD for dysplasia or EGC 16 (8.2) 18 (9.2) 0.858
 MALToma 1 (0.5) 0 (0.0) 1.000
 Reflux esophagitis 1 (0.5) 3 (1.5) 0.615
 Others 10 (5.1) 7 (3.6) 0.620
  1. SQT sequential therapy, PBAT quadruple therapy consist of pantoprazole, bismuth, amoxicillin, and tetracycline, BMI body mass index, EMR endoscopic mucosal resection, ESD endoscopic submucosal dissection, EGC early gastric cancer, MALToma mucosal associated lymphoid tissue lymphoma